Placeholder Banner

BIO Files Amicus Brief Urging Harmonization of Federal Court Frameworks for Determining Patent Obviousness in Patent Litigation

October 16, 2020

BIO filed an amicus brief in the U.S. Court of Appeals for the Federal Circuit on an important and recurring question concerning the framework for determining patent obviousness in patent litigation. BIO argues that courts, when considering whether a patent meets the statutory “nonobviousness” requirement, should consider all evidence for and against the patent’s validity together at the same time. Courts should not use only part of the evidence to conclude that the patent is invalid and then shift the burden to the patent owner.

Related Resources
BIO Files Amicus Brief Urging Harmonization of Federal Court Frameworks for Determining Patent Obviousness in Patent Litigation
Discover More
BIO filed an amicus brief in the Supreme Court of the State of California, encouraging its review of the lower court decision in the Gilead Tenofovir Cases.The Court of Appeal decision operates from a misunderstanding of the drug development and FDA…
The Biotechnology Innovation Organization (“BIO”) respectfully moves the Court for leave to file an amicus brief in support of Plaintiffs’ response in opposition to the Defendants’ cross-motion for summary judgment. Copies of the proposed brief and…
BIO filed an amicus brief in a continuing effort to challenge courts' decisions that undermine FDA authority and hinder patient access to medications.The brief was filed in the Supreme Court of the United States (SCOTUS), following the August 2023…